Expansion of in-house sales of the magLEAD series
First written in FY2016. 5 of 8 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「Building on the MagDEA series of nucleic-acid extraction reagents developed to date, we are seeking to improve nucleic-acid extraction technology and expand nucleic-acid extraction applications compatible with various nucleic-acid amplification methods, next-generation sequencers, and other new gene-detection methods.」
Building on the MagDEA series, the expansion of applications compatible with various nucleic-acid amplification methods and next-generation sequencers continued and became more specific. - FY2025AdvancedAnnual report
「Building on the MagDEA series of nucleic-acid extraction reagents developed to date, we are seeking to improve nucleic-acid extraction technology and expand nucleic-acid extraction applications compatible with various nucleic-acid amplification methods, next-generation sequencers, and other new gene-detection methods.」
Building on the MagDEA series, the expansion of nucleic-acid extraction applications compatible with various nucleic-acid amplification methods and next-generation sequencers became a specific new area of development. - FY2023RestatedAnnual report
「Adding value to DNA/RNA (nucleic-acid) extraction systems (fully automated PCR preparation): “magLEAD 24 Technology”」
In addition to equipping the magLEAD series with nucleic-acid extraction reagents and expanding in-house products, the development policy for automating PCR preparation using magLEAD 24 remained in place. - FY2020RestatedAnnual report
「We are developing genetic extraction reagents and test reagents compatible with multiple specimen types and diagnostic parameters for use with these systems. The genetic extraction reagents are being developed not only for use with the geneLEAD series but also for installation in the magLEAD product line of automated DNA extraction systems, to meet users' diverse automation needs.」
The policy of equipping the magLEAD product line with genetic extraction reagents to meet a broad range of automation needs remained in place. - FY2019RestatedAnnual report
「We are developing genetic extraction reagents for use not only with the geneLEAD series but also with the magLEAD product line of automated DNA extraction systems, to meet users' diverse automation needs.」
The policy of equipping the magLEAD product line with genetic extraction reagents to meet a broad range of automation needs remained in place. - FY2018RestatedAnnual report
「We are developing genetic extraction reagents for use not only with geneLEAD but also with the magLEAD product line, a line of compact automated DNA extraction systems that has entered sales, to meet users' diverse automation needs.」
The policy of equipping the magLEAD product line, which has entered sales, with genetic extraction reagents to meet a broad range of automation needs remained in place. - FY2017RestatedAnnual report
「We are developing genetic extraction reagents for use not only with geneLEAD but also with the magLEAD product line, a line of compact automated DNA extraction systems that has entered sales, to meet users' diverse automation needs.」
The launch of sales of the magLEAD product line and the policy of equipping the line with reagents for geneLEAD were reconfirmed. - FY2016First statedAnnual report
「We designed and developed the new magLEAD 6gC/12gC in accordance with EU Directive 98/79/EC (IVD Directive) and began selling it as an in vitro diagnostic medical device bearing the CE marking. We are also developing the magLEAD 5bL, a high-capacity automated DNA extraction system using a bellows tip. We aim to expand sales of these magLEAD series products as in-house products equipped with our DNA extraction reagents.」
magLEAD 6gC/12gC had received the CE marking and entered sales, while magLEAD 5bL was under development.